Castrate-Resistant Prostate Cancer Market Expected to Reach $29.79 Billion by 2034, Growing at a CAGR of 8.7%

Global Castrate-Resistant Prostate Cancer Market size and share is currently valued at USD 12.92 billion in 2024 and is anticipated to generate an estimated revenue of USD 29.79 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 8.7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

Market Definition

that progress despite androgen-deprivation therapy (ADT). CRPC includes non‑metastatic (nmCRPC) and metastatic (mCRPC) stages, where cancer continues to grow even with low testosterone levels. The market spans multiple treatment classes—hormonal agents (like enzalutamide, apalutamide, abiraterone, darolutamide), chemotherapy, immunotherapies (e.g., sipuleucel‑T), radiopharmaceuticals, and targeted combinations such as PARP inhibitors with hormone therapy. It serves a broad global patient base, including aging populations in North America, Europe, and expanding patient pools in Asia‑Pacific, Latin America, and MEA regions .

Key Report Highlights

The report highlights the key region that accounts for the highest revenue share in the global Castrate-Resistant Prostate Cancer market.
It identifies the leading country within this region that makes a significant contribution to the market’s overall performance.
The report outlines the dominant segment that holds a major share of the market.
It also emphasizes the fastest-growing segment projected to gain strong traction during the forecast period.
Qualitative and quantitative market analysis have been used to provide an in-depth understanding of the market.

Market Overview: Key Figures at a Glance

Market Value in 2024: USD 12.92 billion
Projected Market Size in 2034: USD 29.79 billion
Anticipated CAGR (2025-2034): 8.7%

Get access to the full report or request a complimentary sample for in-depth analysis:

https://www.polarismarketresearch.com/industry-analysis/castrate-resistant-prostate-cancer-market/request-for-sample

Market Growth Drivers

Rising CRPC incidence—fueled by an aging demographic and widespread prostate cancer screening—underpins market growth, with prevalence increasing even after ADT failure. Rapid innovation in molecular-targeted therapies, immunotherapies, radiopharmaceuticals (e.g., 225Ac‑PSMA‑617), and combination regimens like PARP plus AR inhibitors (e.g., niraparib/abiraterone Akeega) is expanding treatment pipelines. Strong clinical and research investment—backed by collaborations among pharma, academia, and regulatory incentives—further accelerates novel approvals . Regionally, mature North American infrastructure dominates innovation uptake, while emerging markets in Asia‑Pacific benefit from rising healthcare spending and enhanced patient awareness

Market Key Players

The competitive landscape features a mix of long-standing companies and emerging contenders. Leading players are actively pursuing R&D initiatives and strategic moves to strengthen their market position. Notable participants include